Flu season visitor restriction – age 16 or older (Restricción de visitantes durante la Temporada de Influenza (Flu) – Mayores de 16 años.)

Flu Season Visitor Restriction

Visitors temporarily restricted to age 16 or older

As a safety first organization, Christiana Care is implementing a temporary visitation age restriction starting Friday, Jan. 18. This temporary restriction protects patients, their loved ones and health care workers during this time of extremely high number of influenza cases and other respiratory illnesses circulating in our community.

The new restrictions limit visitors to patients in Christiana and Wilmington hospitals to persons age 16 or older. Children and teens younger than 16 years are most likely to get the flu and remain contagious longer than adults. This restriction does not apply to outpatient and ambulatory services. We began restricting visitors under the age of 16 years in our Neonatal Intensive Care Unit (NICU) and Women’s and Children’s areas on Jan. 18.

Thank you for your understanding and cooperation.

For more information about the Flu visit our Health Library.

Restricción de visitantes durante la Temporada de Influenza (Flu)

Temporalmente solo se permiten los visitantes mayores de 16 años.

Como una organización que promueve la seguridad ante todo, Christiana Care está implementando una restricción temporal en la edad de visitantes a partir del viernes 18 de enero. Esta restricción temporal protege a los pacientes, a sus seres queridos y al personal de cuidados de salud durante esta época con un número extremadamente alto de casos de influenza y de otras enfermedades respiratorias que circulan en nuestra comunidad.

Las nuevas restricciones, en los hospitales Christiana y Wilmington, sólo permiten visitas a pacientes de personas mayores de 16 años. Los niños y adolescentes menores de 16 años son más propensos a contraer el flu y son contagiosos por más tiempo que los adultos. Esta restricción no aplica a las áreas de servicios ambulatorios. Comenzamos la restricción de visitas a menores de 16 años en nuestra Unidad de Cuidados Intensivos Neonatales (NICU) y en las áreas para Mujeres y Niños desde el 18 de enero.

Gracias por su comprensión y cooperación.

Para más información sobre la gripe, visite nuestra Biblioteca de Salud.

Physicians & Staff

Firas Mourtada, MSE, Ph.D., D.ABR

Chief of Clinical Physics

Firas Mourtada, MSE, Ph.D., D.ABR, is the chief of clinical physics at the Helen F. Graham Cancer Center, where he oversees the delivery of radiation treatments by working side by side with a team of radiation oncologists, physicists, and dosimetrists to ensure patients receive the safest and most effective treatment for cancer. He is also responsible for seeking and integrating cutting-edge radiation oncology technologies into our health system.
Since joining Christiana Care in 2011, Dr. Mourtada also has worked to establish initiatives for clinical trials at the Helen F. Graham Cancer Center as well as clinically oriented research in collaboration with the Center for Translational Cancer Research and within Christiana Care’s Radiation Oncology Department. His own research work at Christiana Care includes a National Institutes of Health-funded grant to investigate a novel dose calculation method for treatment planning of targeted radionuclide therapy. The results could help radiation oncologists better predict how tumors respond to such therapy and the likelihood of cancer recurring and spreading.

Dr. Mourtada has a master’s degree in biomedical engineering from The Johns Hopkins University in Baltimore. He earned his doctorate in radiation health from Johns Hopkins in 1997. He also completed a postdoctoral fellowship at the National Institute of Standards and Technology in Gaithersburg, Md.

Download Dr. Mourtada’s CV.

Selected Research

Summary of Published Work: https://www.researchgate.net/profile/Firas_Mourtada2?ev=prf_highl

Principal Investigator (15%), A Novel Dose Calculation Method for Targeted Radionuclide Therapy, R01 CA138986-01A2, NIH/NCI, 8/5/2010-7/31/2016, $978,495.

Principal Investigator, Evaluation of the Varian Eclipse AXB Dose Algorithm, Sponsored Research Agreement, Varian Medical Systems, 6/2011-12/2012, $20,000.

Co-Investigator (5%), Human Breast Cancer Stem Cell Surrogates, extension to R01 CA138239-01 ($3,053.539), NIH/NCI, Multi-PI- Cristofanilli/Reuben/Woodward, $599,556. 7/1/09-6/30/12.

MDACC Consortium Principal Investigator (2%), Idea Award, Army DOD BCRP BC073879, “Metabolic-Targeted Radionuclide Therapy for the Treatment of Breast Cancer” ($296,000).

MDACC Consortium Principal Investigator (10%), NIH SBIR Phase II proposal 2R44 CA105806-02 with Transpire, Inc., “Deterministic Radiotherapy Calculation Method” ($750,000), 9/2007-6/2011.

Co-Principal Investigator (5%), Development of radiolabeled serotonin transformation agent for imaging neuroendocrine tumors, SRA from Miyagi Clinic Sendai Medical Imaging Center. 6/07-6/09, ($247,000).

Principal Investigator (2%), Inverse Planning Software for Adaptive Intracavitary Brachytherapy, MDACC Technical Review Committee. 10/2006-6/2007 ($65,000).

Principal Investigator (10%), Adaptive Intracavitary Brachytherapy Applicator for Cervical Cancer MDACC Technical Review Committee. 9/2004-9/2005 ($30,000).

Principal Investigator (5%) Institutional Startup Funds, The University of Texas M. D. Anderson Cancer Center. 12/2002-12/2005, $175,000 ($58,333 /year).

Principal Investigator, Commissioning of BEBIG 106Ru/106Rh Eye Plaques: A Practical Clinical Procedure for US Hospitals, SRA from BEBIG. 6/06-6/07, ($10,000).

MDACC Co-Investigator, NIH SBIR Phase I with Transpire, Inc.: Deterministic Radiotherapy Calculation Method, 04/2005-09/2005, CA105806-01A1 ($100,000).

MDACC Principal Investigator, NIH SBIR Phase I with NoviMarte, Inc.: Multi-Purpose Radiopharmaceutical Synthesis Platform, HHSN261200522013C, 08/2005-3/2006, ($100,000).

Principal Investigator, Intravascular Brachytherapy Dosimetry Research, Advanced Cardiovascular Systems, Inc. SR2003-00008635HM 01, 4/7/2003-4/30/2004, ($21,500).

Principal Investigator, Dosimetric Evaluation of Pulsed Dose-rate Brachytherapy for Gynecological Cancer Treatment: A Monte Carlo Study, SRA from Nucletron. 4/04-8/05, ($60,000).

MDACC Principal Investigator, Development of Acuros Dose Engine for Brachytherapy, Radion Technologies SRA. 09/04-09/05 ($38,000).

Principal Investigator, TheraSight? Dosimetry Characterization, SRA from Theragenics Corp. (Period: 6 months, Amount: $7,000).